The Longevity Wire

What's moving in longevity science, translated.

Original short-form coverage of clinical trials, peer-reviewed research, and industry developments — curated from the journals and reporters we actually trust, and read through our evidence lens.

Edited by the IQ Healthspan News Desk

All Research Clinical Industry Regulation

May 11, 2026

Research Neutral

Long-lived families show a head start that begins in childhood, not retirement

A Danish national-registry study finds descendants of exceptionally long-lived families show measurable health and survival advantages early in life — suggesting the longevity phenotype has developmental roots.

Source: Nature Reviews Genetics

→

Apr 30, 2026

Clinical Connected

FDA greenlights the first human trial of partial epigenetic reprogramming

Life Biosciences' ER-100 has cleared FDA to begin the first targeted attempt at cellular age reversal in humans, starting with an eye-disease indication. A real test for the reprogramming hypothesis.

Source: MIT Technology Review

→

Apr 28, 2026

Regulation Neutral

FDA pilots real-time clinical trial monitoring with AstraZeneca and Amgen

The agency will review trial data as it accrues rather than in batched submissions. If the model scales, it could compress timelines for biomarker-heavy geroscience programs.

BioAge oral NLRP3 inhibitor cuts inflammation marker by 85% in Phase 1

BGE-102 dropped median hsCRP by at least 85% in obese adults with elevated baseline inflammation. The cleanest pharmacological validation of the inflammaging thesis we've seen this year.

Source: BioAge Labs

→

Apr 14, 2026

Research Analysis

A nasal spray quiets brain inflammation in aged mice — but "reversed aging" is the wrong headline

An NIA-funded Texas A&M study used intranasal stem-cell-derived extracellular vesicles to reduce neuroinflammation and restore memory in aged mice. The mechanism is plausible — the rejuvenation framing is overcalled.

Source: Texas A&M / Journal of Extracellular Vesicles

→

Mar 30, 2026

Industry Analysis

A stealth biotech is pitching "brainless" human clones as a longevity solution — we think it's a bad detour

R3 Biotechnologies' bodyoid concept — decorticated human-like clones grown as transplant sources — got serious coverage in MIT Technology Review. We explain why the longevity community should push back on this framing.

Source: MIT Technology Review

→

How we work

The IQ Healthspan Wire is produced by the IQ Healthspan News Desk. We monitor a deliberately narrow set of trustworthy outlets — Nature and Nature Aging, MIT Technology Review, STAT News, Endpoints News, Fierce Biotech, FDA press announcements, and NIH/National Institute on Aging research updates. We do not aggregate from wellness publications, social media accounts, or supplement-adjacent outlets.

Every post is written from scratch. We paraphrase the substance; any direct quote is short and attributed; and every post ends with a link to the primary source. We accept no payment from supplement companies, longevity clinics, or pharma. Read more on our News Desk page.